Stanley-Laman Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Stanley-Laman Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$280K	Sell	536 -78	-13%	-$39.9K	0.03%	271
2026 Q2	$305K	Buy	614 +61	+11%	+$27K	0.03%	277
2026 Q1	$247K	Buy	553 +68	+14%	+$31.7K	0.03%	263
2025 Q4	$220K	Buy	+485	New	+$209K	0.03%	267
2025 Q3	–	Sell	-668	Closed	-$297K	–	322
2025 Q2	$297K	Sell	668 -334	-33%	-$154K	0.04%	236
2025 Q1	$486K	Buy	+1,002	New	+$467K	0.07%	198
2024 Q4	–	Sell	-436	Closed	-$203K	–	298
2024 Q3	$203K	Buy	+436	New	+$209K	0.03%	283
2022 Q2	–	Sell	-1,323	Closed	-$345K	–	310
2022 Q1	$345K	Buy	+1,323	New	+$314K	0.05%	215
2021 Q1	–	Sell	-2,168	Closed	-$512K	–	267
2020 Q4	$512K	Buy	2,168 +964	+80%	+$221K	0.09%	209
2020 Q3	$328K	Buy	+1,204	New	+$332K	0.07%	201
2019 Q1	–	Sell	-1,498	Closed	-$248K	–	272
2018 Q4	$248K	Buy	+1,498	New	+$260K	0.07%	231

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

AMF Tjänstepension Stockholm, Sweden $17.2B AUM 28.3% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Montrusco Bolton Investments Montreal, Quebec, Canada $5.77B AUM 24.61% 1-Year Est. Return

Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

ABN AMRO Investment Solutions Paris Cedex 008 $13.2B AUM 30.55% 1-Year Est. Return

Stanley-Laman Group's VRTX Position: Q3 2026 in Review

Stanley-Laman Group reduced its Vertex Pharmaceuticals (VRTX) stake by 13% in Q3 2026, selling an estimated $39.9K and leaving 536 shares worth $280K. The position accounts for 0.03% of the portfolio, ranked #271.

Stanley-Laman Group first reported a position in VRTX in Q4 2018 and has held it in 11 quarters since. The position peaked at $512K in Q4 2020. 439 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

Stanley-Laman Group held 536 shares of Vertex Pharmaceuticals worth $280K as of Q3 2026.
Stanley-Laman Group sold 78 Vertex Pharmaceuticals shares in Q3 2026, an estimated $39.9K.
Vertex Pharmaceuticals made up 0.03% of Stanley-Laman Group's portfolio in Q3 2026, its #271 holding.
Stanley-Laman Group first reported a position in Vertex Pharmaceuticals in Q4 2018 and has held it in 11 quarters since.
Stanley-Laman Group's Vertex Pharmaceuticals position peaked at $512K in Q4 2020.
439 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Stanley-Laman Group's 13F filing for Q3 2026, filed 20 Oct 2026.